Major indices finish lower amid GE earnings disappointment >>> READ MORE

Top 6 Stocks to Buy for September

These stocks should weather the storms of political and economic instability

    View All  

Top Stock to Buy #6 – Santarus (SNTS)

Small-cap biopharmaceutical company Santarus (SNTS) focuses on immediate-release proton pump inhibitors to treat gastrointestinal conditions. The company reported Q2 diluted non-GAAP adjusted earnings of $0.31 versus analysts’ estimates of $0.17. Prescription volume was up 13% from the year-ago quarter.

The company expects earnings of $1.21 to $1.26 this year, which is above the previous guidance of $1.03 to $1.15. It also expects to file four investigational new-drug applications this year and is planning a Phase IIa study on SAN-300, a treatment for rheumatoid arthritis.

Technically, SNTS is in a bull channel that in August ran too far above its 50-day and 200-day moving averages. Despite the strong fundamentals, it was primed for a correction. It has retreated from over $28 in early August and now rests on its bullish support line at just above $22, where it should be bought. The trading target for SNTS is $28, but it could catch fire and beat that target by a wide margin.

SNTS Chart
Click to Enlarge

Chart Key


Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC